<DOC>
<DOCNO>1070510_business_story_7757728.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Lupin net rises to Rs 137cr

 Mumbai, May 9 (PTI): Lupin has reported close to a three-fold growth in net profit at Rs 137.08 crore for the three months ended March 31, 2007 against Rs 50.19 crore in the year-ago period.

 Total income (net of excise) of the pharmaceutical firm rose nearly 40 per cent to Rs 646.40 crore for the fourth quarter against Rs 463.02 crore in the same period a year ago, Lupin informed the Bombay Stock Exchange.

 The companys board of directors has recommended 50 per cent dividend at Rs 5 per equity share at a face value of Rs 10 each for the year ended March 31, 2007.

 Lupin recorded a 65.3 per cent growth in net profit at Rs 302.06 crore against Rs 182.72 crore in the previous fiscal. 

 Total income (net of excise) also grew by 28.53 per cent to Rs 2,157.58 crore in the 12 months ended March 31, 2007 from Rs 1,678.61 crore last year.

 In a move that would enhance its presence in the active pharmaceutical ingredients (API) market, the Lupin board of directors has given its nod to set up a local subsidiary at an investment of Rs 5 lakh. The subsidiary would manufacture API at a unit, which would be located in a special economic zone.

 The board has also approved the formation of a wholly owned subsidiary in Switzerland at an investment of up to Swiss francs 100,000. The proposed subsidiary would act as a vehicle to route overseas investments. 

 On a consolidated basis, the group, which exports products to the US, Europe, Southeast Asia, Japan and China, recorded a net profit after minority interest at Rs 141.14 crore and its total income (net of excise) was Rs 665.63 crore for the fourth quarter.

 For 2006-07, the groups net profit after minority interest touched Rs 308.56 crore and total income (net of excise) was Rs 2,212.76 crore. Lupin shares were last trading at Rs 708, down two per cent, on the BSE.




</TEXT>
</DOC>